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Abstract
Introduction. Women with postmenopausal bleeding and endometrial thickness
>4 mm undergo endometrial sampling to exclude endometrial cancer. The aim of
this study is to investigate the relative risk of developing endometrial cancer in a
prospective cohort after initial work-up for postmenopausal bleeding showing
reassuring histology or insufficient sampling. Material and methods. All women
presenting with postmenopausal bleeding were prospectively included from
January 2009 to April 2011. Follow-up data were collected from patient charts
and PALGA (Dutch Pathology Registry). Hazard ratios for endometrial cancer
were determined by calculating standardized incidence ratios. Results. A total of
668 women were included and 568 women were available for follow-up [median
follow-up time 47 (range 7–63) months]. Women who presented with
postmenopausal bleeding, endometrial thickness >4 mm and hyperplasia
without atypia on biopsy at the first presentation showed a significantly
increased risk (standardized incidence ratio 17.15, 95% confidence interval 1.96–
61.93) of being diagnosed with endometrial cancer during the first four years of
follow up compared with the age-specific population. All women that developed
endometrial cancer after initial reassuring histology presented with recurrent
postmenopausal bleeding. None of the women with endometrial thickness
>4 mm and no or insufficient sample for histology at the first presentation
developed endometrial cancer during the follow up. Conclusions. Although in
general, women with endometrial hyperplasia without atypia are considered to
have a low risk for cancer, we observed a significant long-term risk of
endometrial cancer after postmenopausal bleeding. Whether additional
diagnostics or a more stringent follow-up regimen would be cost-effective, needs
to be studied.
Abbreviations: BMI, body mass index; SIR, standardized incidence ratio.
Introduction
Endometrial cancer is the most common gynecologic
malignancy in industrialized countries (1). The prevalence
of a malignancy of the endometrium among women pre-
senting with postmenopausal bleeding increases with age,
from <1% of women aged under 50 years up to 24% of
women aged over 80 years (2). International guidelines
recommend measurement of the endometrial thickness by
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transvaginal ultrasound in case of postmenopausal bleed-
ing (3,4). In women with an endometrial thickness
≤4 mm, there is a very low risk of finding pathological
endometrium on biopsy or curettage, therefore refraining
from these procedures is considered justified (4,5). In
case of an endometrial thickness >4 mm, outpatient
endometrial sampling is indicated to exclude endometrial
cancer (3,4,6). When endometrial sampling reveals reas-
suring histology and hysteroscopic biopsy or saline con-
trast sonohysterography shows no abnormalities, women
are discharged from follow up and instructed to contact
the gynecologist in case of recurrent postmenopausal
bleeding (4). Although histological finding of endometrial
hyperplasia without atypia has a slightly increased risk for
developing endometrial cancer, it is generally regarded as
reassuring.
In our recently published prospective cohort study we
showed that in 74 (20.8%) of 356 women presenting with
postmenopausal bleeding and endometrial thickness
>4 mm, outpatient endometrial sampling technically
failed, and in 84 (29.8%) the amount of tissue was insuf-
ficient for a histopathological diagnosis (7). Currently,
there is no consensus on what to do after failure of out-
patient endometrial sampling. Some guidelines recom-
mend additional hysteroscopy in all patients, whereas
others incorporate risk factors in the decision to obtain
histology after first insufficient tissue sample (4,8–10).
Previous studies reported (pre)malignancies of the endo-
metrium in up to 20% of the women after failure of out-
patient endometrial sampling (11–14). Despite this
knowledge, no further histopathological examination was
performed in 45% of women with an insufficient sample
(7). To our knowledge, there are no long-term follow-up
studies reporting on the incidence of endometrial cancer
after failure of endometrial sampling. We hypothesized an
increased risk of endometrial (pre)malignancies in women
with postmenopausal bleeding and failure of endometrial
sampling.
The aim of this long-term follow-up study was to
investigate the relative risk of developing endometrial
(pre)malignancies after initial work-up for post-
menopausal bleeding showing reassuring histology or
insufficient endometrial sampling.
Material and methods
The current prospective cohort consisted of women pre-
senting with postmenopausal bleeding at TweeSteden
Hospital, Tilburg, Maxima Medical Center, Veldhoven
and St. Antonius Hospital, Nieuwegein, from January
2009 to April 2011, as previously reported (7). Post-
menopausal bleeding was defined as one-time or recur-
rent vaginal bleeding after a period of at least 12 months
of amenorrhea. The diagnostic work-up of all patients
was performed in one of the three participating hospitals.
According to the guidelines of the Dutch Society of
Obstetrics and Gynecology (4), the diagnostic work-up
consisted of a double-layer measurement of the endome-
trium by transvaginal ultrasound and a cervical smear.
Women with a first episode of postmenopausal bleeding
and an endometrial thickness ≤4 mm were reassured and
instructed to contact the gynecologist in case of recurrent
postmenopausal bleeding. When endometrial thickness
was >4 mm, not measurable, or in case of persistent or
recurrent postmenopausal bleeding, endometrium biopsy
was performed using Pipelle endometrial sampling
(Pipelle de Cornier, Paris, France) and sent for histologi-
cal examination. In case of failure of endometrial sam-
pling, repeated endometrial sampling, hysteroscopic
biopsy or dilatation and curettage could be performed.
Failure of endometrial sampling was classified as either
endometrial sampling that could not be performed (tech-
nical failure) or as endometrial sampling in which the
procedure was performed but the amount of tissue was
insufficient for a reliable histopathological diagnosis (in-
sufficient sampling). Histological diagnosis was made by
the pathologists of the participating centers specialized in
gynecological pathology. Normal proliferative or atrophic
endometrium, and endometrial polyps were considered as
benign. Hyperplasia without atypia was, according to the
Dutch guidelines, considered a reassuring histology with-
out the need for further follow up, despite a slightly
increased risk of endometrial cancer. Both simple atypical
hyperplasia and complex atypical hyperplasia were con-
sidered premalignancy. According to these guidelines a
hysterectomy was recommended for women initially diag-
nosed with atypical hyperplasia or endometrial cancer.
For this long-term follow-up study, data were collected
from the patient charts of the three participating clinics.
Follow-up data were evaluated up to March 2014. All
consultations for postmenopausal bleeding or possibly
related complaints such as an abnormal cervical smear,
abdominal pain or an increased abdominal circumference
were recorded. The reason for consultation, measurement
of the double-layer endometrium by transvaginal ultra-
sound and the results of diagnostic work-up were
reported.
Key Message
Women with recurrent postmenopausal bleeding have
a significant risk of endometrial cancer at follow up
despite an initial reassuring histological finding of
endometrial hyperplasia without atypia.
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An additional comprehensive search in the nationwide
network and registry of histo- and cytopathology in the
Netherlands (PALGA) was performed to cross-reference
follow-up data. PALGA has reached complete national
coverage since 1991 (15). In this way, data from the
patient charts could be confirmed and loss from follow up,
for example due to moving to another city, was precluded.
We registered all (pre)malignant lesions of the uterus and
cervix and all ovarian and colorectal cancers during follow
up. Discrepancies between data from the patient charts
and PALGA were discussed to reach consensus.
No ethical approval was needed for this observational
study according to the Code of Conduct for the use of
data in Health Research (Dutch Federation of Biomedical
Scientific Societies, http://www.federa.org).
Statistical analysis
Statistical analysis was performed with IBM SPSS Statis-
tics 20.0 (IBM Corporation, Somers, NY, USA). Women
were followed from the date of first presentation up to
March 2014, or until the diagnosis of endometrial cancer,
cervical cancer, ovarian cancer or hysterectomy. The risk
of endometrial cancer, relative to the general population,
was estimated with standardized incidence ratios (SIRs).
The SIR was calculated by dividing the observed inci-
dence by the expected incidence of cancer cases. The
expected incidence of cancer was estimated by multiply-
ing the number of person-years with the age-specific inci-
dence rates. The age-specific incidence rates, stratified by
five-year age groups, were obtained from the Netherlands
Cancer Registry, which is managed by the Netherlands
Comprehensive Cancer Organization (IKNL). 95% Confi-
dence intervals (CI) were calculated.
Results
A total of 668 women presented with postmenopausal
bleeding. At first presentation endometrial thickness was
≤4 mm in 36.7% (n = 245), >4 mm in 53.4% (n = 357)
and unknown in 9.9% (n = 66). All patient characteristics
are summarized in Table 1.
In 73 women, endometrial cancer was diagnosed after
work-up at first presentation (10.6%) (Figure 1). Of these
73 women, 34 had an initial diagnosis based on Pipelle
endometrial sampling, 28 on hysteroscopic biopsy, six on
dilation and curettage, and in five a hysterectomy was per-
formed without prior histological diagnosis of endometrial
cancer or atypical hyperplasia. Most of these women
(74.0%) had an endometrial thickness >4 mm (n = 54), in
23.3% (n = 17) endometrial thickness was unknown, and
in 2.7% (n = 2) endometrial thickness was ≤4 mm. Eight
women were diagnosed with atypical hyperplasia (1.2%),
four women with cervical cancer (0.6%) and one woman
with colorectal cancer (0.1%). A hysterectomy showing
benign histology was performed in 14 women.
A total of 568 women were available for follow up. The
median follow-up time was 47 (range 7–63) months.
During follow up, eight women were diagnosed with
endometrial cancer (1.4%) (Figure 1). The incidence of
endometrial cancer was the highest in the group of
women with an endometrial thickness >4 mm at first
presentation (n = 6; 2.1%). Four women initially had
benign endometrial histology obtained by endometrial
sampling, hysteroscopic biopsy or curettage and two
women hyperplasia without atypia (Figure 2). Their med-
ian age of diagnosis was 68 years (range 63–79), and
endometrial cancer was diagnosed after a median follow
up of 18 months (range 9–24). During follow up these
women with a final diagnosis of endometrial cancer pre-
sented with recurrent postmenopausal bleeding and
underwent endometrial biopsy or curettage in which
atypical hyperplasia (n = 2) or endometrial cancer
(n = 4) was diagnosed. Among all women available for
follow up (n = 568) there was no significant difference in
body mass index (BMI), presence of diabetes, hyperten-
sion or use of hormone replacement therapy, between
women who developed endometrial cancer and those who
did not. However, women who developed endometrial
cancer were significantly older at first presentation than
were women without endometrial cancer (p = 0.002),
Table 1. Baseline clinical characteristics of the postmenopausal
women at first presentation. Values are presented as median (range)
or number (%).
Characteristics of the
women
Total
(n = 668)
Available for follow up
(n = 568)
Age, years 59 (35–93) 58 (41–91)
Body mass index, kg/m2 28 (17–77) 28 (17–77)
Time since menopause,
years
6 (1–50) 5 (1–50)
Endometrial thickness
≤4 mm 245 (36.7) 241 (42.4)
>4 mm 357 (53.4) 285 (50.2)
Unknown 66 (9.9) 42 (7.4)
Hormone replacement therapy
Yes 50 (7.5) 34 (6.0)
No 601 (90.0) 518 (91.2)
Unknown 17 (2.5) 16 (2.8)
Hypertension
Yes 230 (34.4) 179 (31.5)
No 419 (62.7) 371 (65.3)
Unknown 19 (2.8) 18 (3.2)
Diabetes mellitus
Yes 86 (12.9) 62 (10.9)
No 562 (84.1) 487 (85.7)
Unknown 20 (3.0) 19 (3.3)
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median age 68 and 58 years, respectively. This difference
in age at first presentation was also seen among women
with an initial endometrial thickness >4 mm (p = 0.009).
Incidence rates found in this study were compared with
age-specific incidence rates as reported by the Nether-
lands Cancer Registry. We found that women who
presented with postmenopausal bleeding, an endometrial
thickness >4 mm and hyperplasia without atypia at first
presentation have a 17 times increased risk (SIR 17.15,
95% CI 1.93–61.93) of developing endometrial cancer
during follow up compared with the age-specific popula-
tion (Table 2). Exclusion of women using hormone
Figure 1. Results of follow up in women presenting with postmenopausal bleeding (PMB) stratified by initial endometrial thickness (ET).
Figure 2. Results of follow up in women presenting with postmenopausal bleeding and initial endometrial thickness (ET) >4 mm stratified by
initial biopsy results.
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replacement therapy did not change conclusions. No
endometrial cancer was diagnosed during follow up in
women with an endometrial thickness >4 mm and no or
insufficient histology at first presentation. Although for
the whole cohort, women with initial insufficient histol-
ogy had thinner endometrium than women with suffi-
cient material for diagnosis (median endometrial
thickness 5.8 mm vs. 8.0 mm, p < 0.001), there was no
significant difference in endometrial thickness between
these two groups when their endometrial thickness was
>4 mm (median endometrial thickness 7.4 mm vs.
9 mm, p = 0.078).
Discussion
Women presenting with postmenopausal bleeding,
endometrial thickness >4 mm and hyperplasia without
atypia at initial work-up, have a significantly increased
risk of developing endometrial cancer during four years
of follow up compared with the age-specific population.
In contrast to our hypothesis, we did not find endome-
trial cancer during follow up in women with endometrial
thickness >4 mm and no or insufficient histology at ini-
tial presentation. To our knowledge, this is the first study
that identified the incidence of endometrial cancer during
long-term follow up stratified by endometrial thickness
and histological diagnosis at initial presentation.
The strength of this study is that it is a well-documen-
ted, multicenter prospective cohort study, including a
large number of women. Loss of follow up was mini-
mized using an additional comprehensive search in
PALGA. Incidence rates of endometrial cancer were com-
pared with the age-specific incidence of the Netherland’s
Cancer Registry, managed by the Netherlands Compre-
hensive Cancer Organization (IKNL). Still, the number of
women in some subgroups during follow up was rela-
tively small, hampering the comparison of different
groups. There was no central pathology revision which
could both over- or underestimate the incidence of
endometrial (pre)malignancies (16,17).
Hyperplasia without atypia,is regarded as reassuring
histology due to the small (1–3%) risk of progression to
endometrial cancer (18). As a consequence, follow up of
this group of patients is not routinely recommended.
Atypical hyperplasia, on the contrary, has a substantial
risk of progression to carcinoma (8% of simple atypical
hyperplasia, and 29% of complex atypical hyperplasia)
(18). Only a few other studies report on the endometrial
cancer risk of endometrial hyperplasias. Lacey et al.
observed a relative risk (RR) of 2.0 for simple hyperplasia
and 2.8 for complex hyperplasia to progress to endome-
trial cancer compared with 48 for atypical hyperplasia
after one to five years of follow up (19). In our study the
risk of endometrial cancer was compared with that in the
general population. We observed that women with an
endometrial thickness >4 mm and hyperplasia without
atypia had a 17-fold increased risk compared with the
age-specific incidence in the Dutch population.
In our cohort, four of eight cases of endometrial cancer
during follow up were diagnosed in women who initially
had benign histology. These findings are in line with
results of a recent meta-analysis that demonstrated that
endometrial sampling is very accurate in diagnosing
endometrial cancer, but less accurate in ruling
out endometrial cancer (20). A large randomized
controlled trial and two retrospective studies have shown
that hysteroscopy contributed to the detection of focal
(pre)malignancies in women with postmenopausal bleed-
ing and thickened endometrium with benign histology
(21–23). In our cohort, 43 women (25.4%) underwent an
additional hysteroscopy with benign histology on Pipelle
endometrial sampling, resulting in one patient with
endometrial cancer, and three with atypical hyperplasia.
These findings are in line with the data of van Hanegem
et al. (23) and demonstrate that we might underestimate
the risk of (pre)malignancies in women with thickened
endometrium that only had Pipelle endometrial sampling.
Yet, due to a relatively long follow up of 47 months, it is
unlikely that we missed a substantial number of cases
with (pre)malignancies.
Table 2. Standardized incidence ratios for women presenting with postmenopausal bleeding.
Endometrial thickness Initial histology Age n Person years
Endometrial cancer
SIR 95% CI
≤4 mm All All 241 959 0.90 0.10–3.26
>4 mm All All 285 1112 2.34 0.85–5.08
Benign All 224 878 1.97 0.53–5.05
Hyperplasia
without atypia
All 14 50 17.15 1.93–61.93
Unknown All All 42 167 NA NA
Total All All 568 2239 1.55 0.67–3.05
SIR, standardized incidence ratio.
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We hypothesized that women with postmenopausal
bleeding and failure of endometrial sampling were at an
increased risk of endometrial (pre)malignancies, but our
study could not confirm this. It is remarkable that in
79% (45/57) of the women with initial no, or insufficient,
histology and endometrial thickness >4 mm, no histology
was obtained by repeated sampling or hysteroscopic
biopsy. There is no consensus in international guidelines
on the recommendations after failure of endometrial sam-
pling. Some guidelines recommend standard hysteroscopy
with biopsy or curettage in case of failure of outpatient
endometrial sampling, whereas others only recommend
further investigation in case of risk factors for endome-
trial cancer or persistent bleeding (11–14). The committee
opinion of the American College of Obstetrics and Gyne-
cology recommends transvaginal ultrasound after insuffi-
cient sample and further investigation in case of
endometrial thickness >4 mm (10).
In conclusion, women with initial hyperplasia without
atypia seem to have a significantly increased risk of devel-
oping endometrial cancer during the first four years of
follow up, whereas none of the women with endometrial
thickness >4 mm and no, or insufficient, histology at first
presentation developed endometrial cancer. Although
recent studies suggest that further diagnostic work-up in
case of benign histology is recommended to exclude focal
endometrial (pre)malignancy (20–23), all women in our
study that developed endometrial cancer after initial
benign histology or hyperplasia without atypia, presented
with recurrent postmenopausal bleeding, and were diag-
nosed with early stage disease. Therefore, based on these
data, we cannot yet recommend the need for additional
work-up. Whether additional diagnostics or a more strin-
gent follow-up regimen in these women is cost-effective
needs to be studied.
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